E
EBVio is a preclinical therapeutics company focused on developing novel treatments for Epstein-Barr Virus (EBV)-driven autoimmune diseases. The company is creating first-in-class precision medicines designed to address the underlying cause of these conditions. This approach aims to provide targeted therapeutic options where current treatments may be insufficient.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- EBVio is a preclinical therapeutics company focused on developing novel treatments for autoimmune diseases. The company targets the underlying cause of these conditions, specifically those driven by the Epstein-Barr virus (EBV). Their pipeline aims to deliver first-in-class precision medicines to address significant unmet medical needs in this therapeutic area.